Organisation paid for research Program year 2025 Source: CMS Open Payments

Austin Epilepsy Care Center

Neither a doctor nor a teaching hospital

Research payments

$504,090

143 payments

Through program year 2025, Austin Epilepsy Care Center is reported as receiving $504,090 in research payments, across 143 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$2,121	1
2024	Research	$5,160	4
2023	Research	$45,341	11
2022	Research	$13,235	5
2021	Research	$72,675	11
2020	Research	$222,187	26
2019	Research	$143,371	85

Breakdown

Who paid Research payments · program years 2019–2025

SK Life Science, Inc. $148,886 24 payments
Sunovion Pharmaceuticals Inc. $96,109 77 payments
Aquestive Therapeutics, Inc. $82,896 6 payments
Ucb SA $52,907 7 payments
Jazz Pharmaceuticals Inc. $49,014 13 payments
UCB Biosciences Inc. $41,755 10 payments
UCB, Inc. $16,216 1 payment
Eisai Inc. $8,868 4 payments
GW Research Limited $7,440 1 payment

Studies the money was for Research payments · program years 2019–2025

A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures $96,109 77 payments
Safety and Tolerability Study of Diazepam Buccal Soluble Film DBSF in Subjects With Epilepsy $62,110 2 payments
A Long-Term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution $49,014 13 payments
059566 $47,912 2 payments
59566 $45,928 6 payments
Phase II/III AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL-ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPS $22,406 2 payments
A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Evaluate the Efficacy and Safety of Padsevonil As Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy $20,653 1 payment
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects with Partial Onset Seizures $17,568 3 payments
Multicenter 1 Year Observational Study of Patients Who Are Initiating Brivaracetam. $16,216 1 payment
Ykp509c003 $14,500 6 payments

What the money was spent on Research payments · program years 2019–2025

Patient care $71,855 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.